Abstract 4554
Background
Obesity is a chief mediator of endometrial cancer (EC) and is responsible for the increasing incidence and mortality of this malignancy. Obesity induced chronic inflammation, creates a pro-neoplastic environment via local and systemic processes. In other obesity-related cancers, white adipose tissue inflammation (WATi) is an independent predictor of shortened cancer-specific survival. A retrospective study in advanced EC revealed that WATi is associated with shorter progression-free survival. The aim of this prospective study was to investigate the presence of WATi in EC and to evaluate the relationship between WATi and clinicopathologic factors in women with EC.
Methods
Patients who underwent primary surgical management of EC, regardless of stage or histology, had omental biopsies collected. WATi was detected by the presence of dead/dying adipocytes surrounded by CD68+ macrophages forming a crown-like structure (CLS). Clinicopathologic data were extracted from medical records. For association with WATi, Wilcoxon rank sum test was used for continuous variables, and the Fisher’s exact or χ2 test for categorical variables.
Results
A total of 101 EC patients who underwent primary surgical management between 2015 and 2019 were included. Of these, 46 (46%) had WATi. The presence of WATi was unaffected by race, histology, FIGO stage, smoking or menopausal state. In contrast, dyslipidemia (39% vs 13%, p = 0.002), hypertension (70% vs 35%, p < 0.001) and diabetes mellitus (13% vs 9%, p = 0.015) were significantly more frequent in EC patients with WATi. The median BMI was 35 kg/m2 and 29 kg/m2 in the WATi versus non WATi patients, respectively (p < 0.001). The median CLS based on BMI was 0.19 CLS/cm2 for those with a BMI of < 25kg/m2, 0.34 CLS/cm2 for those with a BMI of 25-29kg/m2, and 1.01 CLS/cm2 for those with a BMI of > 30kg/m2.
Conclusions
WATi was present in nearly 50% of newly diagnosed EC patients regardless of stage. There was an association between the presence and severity of WATi and BMI among patients with EC. Specifically, WATi was associated with hyperglycemia, hypertension, and diabetes mellitus. Further investigation into the impact of WATi on the tumor microenvironment and patient outcomes is ongoing.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
4546 - Efficacy and toxicity of weekly carboplatin and paclitaxel as induction or palliative treatment in advanced esophageal cancer patients
Presenter: Femke de Man
Session: Poster Display session 2
Resources:
Abstract
5908 - Perioperative chemotherapy with Docetaxel, Oxaliplatin, Fluorouracil and Leucovorin (FLOT) versus Epirubicin, Platinum and Capecitabine or Flourouracil (EOX/ECF) in Resectable Gastric or Gastroesophageal Junction Adenocarcinoma- Safety and response data from India.
Presenter: Tanuj Chawla
Session: Poster Display session 2
Resources:
Abstract
937 - Phase II Study of Preoperative Radiotherapy Combined with S-1 plus Cisplatin in Clinically Resectable Type 4 or Large Type 3 Gastric Cancer: OGSG1205
Presenter: Shunji Endo
Session: Poster Display session 2
Resources:
Abstract
1119 - Observational Study of the Peritoneal Washing Cytology Positive Gastric Cancer without Gross Peritoneal Metastasis Underwent Radical D2 Gastrectomy.
Presenter: Jun Eul Hwang
Session: Poster Display session 2
Resources:
Abstract
3744 - Primary results of multicenter phase II study of neoadjuvant chemotherapy with S-1 and oxaliplatin for locally advanced gastric cancer (Neo G-SOX PII)
Presenter: Akira Miki
Session: Poster Display session 2
Resources:
Abstract
5091 - Multicenter Phase I/II Feasibility Study of Adjuvant Treatment with S-1 in Patients after R0-Resection of Adenocarcinoma of the Stomach and Esophagogastric Junction (GMBH-STO-0114)
Presenter: Kathrin Heinrich
Session: Poster Display session 2
Resources:
Abstract
2891 - A phase I study of Docetaxel/Oxaliplatin/S-1 (DOS) combination neoadjuvant chemotherapy for patients with locally advanced adenocarcinoma of the esophagogastric junction
Presenter: Kei Hosoda
Session: Poster Display session 2
Resources:
Abstract
2994 - Apatinib combined with docetaxel in second-line treatment of advanced gastric cancer: a prospective clinical study (Data updated)
Presenter: Mudan Yang
Session: Poster Display session 2
Resources:
Abstract
3000 - A multicenter phase II study of TAS-114 in combination with S-1 in patients with pre-treated advanced gastric cancer (EPOC1604)
Presenter: Daisuke Takahari
Session: Poster Display session 2
Resources:
Abstract
4653 - Impact of Pembrolizumab (pembro) Versus Paclitaxel on Health-Related Quality of Life (HRQoL) in Patients With Advanced Gastric or Gastroesophageal Junction (GEJ) Cancer That Has Progressed After First-Line Chemotherapy (KEYNOTE-061)
Presenter: Eric Van Cutsem
Session: Poster Display session 2
Resources:
Abstract